Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / ocugen advances phase 1 2 trial for eye disease cand

ALPMY - Ocugen advances Phase 1/2 trial for eye disease candidate

Astellas Pharma Inc. ADR

2024-04-05 10:56:25 ET

More on Ocugen

For further details see:

Ocugen advances Phase 1/2 trial for eye disease candidate
Stock Information
Company Name: Astellas Pharma Inc. ADR
Stock Symbol: ALPMY
Market: OTC
Menu
ALPMY ALPMY Quote ALPMY Short ALPMY News ALPMY Articles ALPMY Message Board
Get ALPMY Alerts

News, Short Squeeze, Breakout and More Instantly...